Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors ; volume:59 ; number:1 ; day:18 ; month:10 ; year:2024 ; pages:1-6 ; date:12.2024
Blood research ; 59, Heft 1 (18.10.2024), 1-6, 12.2024
- Creator
-
Kim, Sung Eun
Kim, Ji Yoon
Park, Jeong A.
Lyu, Chuhl Joo
Hahn, Seung Min
Han, Jung Woo
Park, Young Shil
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s44313-024-00039-1
- URN
-
urn:nbn:de:101:1-2501072124147.125188141058
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Sung Eun
- Kim, Ji Yoon
- Park, Jeong A.
- Lyu, Chuhl Joo
- Hahn, Seung Min
- Han, Jung Woo
- Park, Young Shil
- SpringerLink (Online service)
Other Objects (12)
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting
Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Femoral Fractures in Severe Hemophilia
Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia
Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia
Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
A Response to: Letter to the Editor Regarding “Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China”
Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis